As previously reported, 15 out of 16 (94%) patients in Phase 2b in the Per Protocol Population experienced Clinical Cure (CC) and all 15 of 15 (100%) remained free ...

A study that claims the popular OsteoStrong program can help strengthen bones in post-menopausal women is "misleading", and ...

Incannex Healthcare Inc. (NASDAQ: IXHL) shares barely budged. The New York-based company, a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, ...

Researchers at the Case Western Reserve School of Medicine have found that semaglutide, a popular diabetes and weight-loss ...

Adial refines Phase 3 plans for AD04 in Alcohol Use Disorder, focusing on genetic subgroups and leveraging Cytel's advanced trial design expertise.

Top-line results expected July 2025 as development of first-in-class OSA drug advancesNEW YORK and MELBOURNE, Australia, June 18, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) ...

The program included five pivotal trials, which evaluated the efficacy and safety of Mounjaro as a monotherapy, and as an add-on to standard therapies for type 2 diabetes.

Researchers at the Case Western Reserve School of Medicine have found that semaglutide, a popular diabetes and weight-loss ...

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary ...